Not cost-effective at zero price: valuing and paying for combination therapies in cancer

Nicholas R Latimera Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, UKCorrespondence[email protected]

https://orcid.org/0000-0001-5304-5585 View further author information

Adrian Towseb Office of Health Economics, London, UKView further author information

Chris Henshallb Office of Health Economics, London, UKView further author information

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (7)

Afschin Gandjour. (2023) Value-based pricing of add-on life-extending medicines based on economic evaluation. British Journal of Healthcare Management 29:8, pages 1-7.
Crossref

Narcyz Ghinea, Wendy Lipworth, Ian Kerridge & John R. Zalcberg. (2023) How therapeutic advances have transformed the medical landscape: a primer for clinicians. Internal Medicine Journal 53:8, pages 1306-1310.
Crossref

Julie M. Vancoppenolle, Simone N. Koole, James F. O'Mahony, Nora Franzen, Jacobus A. Burgers, Valesca P. Retèl & Willem H. van Harten. (2023) Targeted combination therapies in oncology: Challenging regulatory frameworks designed for monotherapies in Europe. Drug Discovery Today 28:8, pages 103620.
Crossref

Christopher H. Henshall, Dávid Dankó, Leela Barham, Jaime Espín, Jorge Felix, Mary Harney, Peter Indra, Jorge Mestre-Ferrandiz, Gérard de Pouvourville, Federico Spandonaro, Luka Vončina & Nils Wilking. (2023) Review and Assessment of Policy Options for Improving Access to Combination Therapies in Oncology in Europe. Applied Health Economics and Health Policy 21:4, pages 537-546.
Crossref

Zhe Xu, Zhuo‐miao Ye, Yu‐kai Tang, Dong‐feng Deng, Qin Zhou, Man Fang, Ying‐ying Zhang & Xiang‐ping Li. (2023) Cost‐effectiveness analysis of sintilimab plus IBI305 versus sorafenib for unresectable hepatic cell carcinoma in China . Cancer Medicine 12:14, pages 14871-14880.
Crossref

Remziye Zaim, Ken Redekop & Carin A. Uyl-de Groot. (2022) Attribution of Value for Combination Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer. Journal of Cancer Policy, pages 100382.
Crossref

Nicholas. R Latimer, Daniel Pollard, Adrian Towse, Chris Henshall, Lloyd Sansom, Robyn L Ward, Andrew Bruce & Carla Deakin. (2021) Challenges in valuing and paying for combination regimens in oncology: reporting the perspectives of a multi‐stakeholder, international workshop. BMC Health Services Research 21:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Not cost-effective at zero price: valuing and paying for combination therapies in cancer

Articles from other publishers (7)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Not cost-effective at zero price: valuing and paying for combination therapies in cancer

Citations (7)

Articles from other publishers (7)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date